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Mammals transport blood through a high-pressure, closed vascular network and lymph through a low- 
pressure, open vascular network. These vascular networks connect at the lymphovenous (LV) junction, 
where lymph drains into blood and an LV valve (LVV) prevents backflow of blood into lymphatic vessels. 
Here we describe an essential role for platelets in preventing blood from entering the lymphatic system at 
the LV junction. Loss of CLEC2, a receptor that activates platelets in response to lymphatic endothelial cells, 
resulted in backfilling of the lymphatic network with blood from the thoracic duct (TD) in both neonatal 
and mature mice. Fibrin-containing platelet thrombi were observed at the LVV and in the terminal TD in 
wild-type mice, but not Clec2-deficient mice. Analysis of mice lacking LVVs or lymphatic valves revealed that 
platelet-mediated thrombus formation limits LV backflow under conditions of impaired valve function. 
Examination of mice lacking integrin-mediated platelet aggregation indicated that platelet aggregation sta-
bilizes thrombi that form in the lymphatic vascular environment to prevent retrograde blood flow. Collec-
tively, these studies unveil a newly recognized form of hemostasis that functions with the LVV to safeguard 
the lymphatic vascular network throughout life.
Introduction
The mammalian cardiovascular system is divided into distinct 
blood and lymphatic vascular networks: blood is transported to 
the tissues in a closed, high-pressure vascular system, and intersti-
tial fluid is transported from the tissues in an open, low-pressure 
vascular system (1). These structurally and functionally distinct 
vascular networks must remain separate to function properly, yet 
they must also connect in order for lymph fluid and immune cells 
to be returned to the blood. A bicuspid lymphovenous valve (LVV) 
is believed to safeguard this connection and prevent blood from 
entering the lower-pressure lymphatic system and blocking for-
ward lymphatic flow. In humans, LVVs reside in 2 locations: the 
thoracic duct–subclavian vein (TD-SV) junction on the left, and 
the right lymphatic duct–SV junction on the right (2).
Recent genetic studies in mice have revealed an unexpected 
mechanism, in which platelet C-type lectin–like receptor 2 (CLEC2) 
signaling in response to the surface protein podoplanin (PDPN) 
expressed on lymphatic endothelial cells (LECs) is required for nor-
mal lymphatic development and function. Mice deficient in PDPN, 
CLEC2, or the CLEC2 signaling proteins SYK and SLP-76 exhibit 
blood-filled lymphatics during fetal life and die shortly after birth 
due to defective lymphatic function (3–6). Tissue-specific deletion 
experiments reveal that CLEC2 and its intracellular signaling effec-
tors are required in platelets, while PDPN is required in endothelial 
cells to prevent this phenotype (4–7). In addition, studies of mature 
mice reconstituted with hematopoietic cells deficient in Clec2, 
Syk, or SLP-76, as well as mature mice in which PDPN expression 
is ablated through conditional deletion of the O-glycan synthase 
enzyme required for its expression, revealed that this pathway is 
also required in mature animals to prevent blood-filled lymphatics 
and death due to lymphatic dysfunction (3, 4, 8, 9).
How platelet activation by LECs maintains separation of the 
blood and lymphatic vascular networks has not been clear. Some 
groups have reported that platelet activation by CLEC2 signal-
ing may regulate LEC growth in vitro through secretion of plate-
let granule contents (6, 10). However, we have not observed such 
effects on LEC growth in vitro or detected major defects in the 
pattern or rate of lymphatic vascular development in vivo (8, 11), 
and how such an angiogenic mechanism would explain an ongo-
ing requirement in mature, presumably nonangiogenic, animals 
is not clear. Understanding the role of platelet CLEC2 signaling in 
lymphatic growth and function has acquired particular urgency 
with the recent development and clinical application of therapeu-
tic agents that block SYK, a nonreceptor tyrosine kinase that is 
required for CLEC2 signaling in platelets.
A major hurdle in understanding this pathway has been defin-
ing precisely when and where platelets in circulating blood come 
into contact with LECs to initiate PDPN-CLEC2 signaling. We 
and others have identified platelets in contact with newly speci-
fied LECs in the cardinal vein of E11.5 mouse embryos (4, 12), but 
venous LEC specification is complete by E14.5 and cannot explain 
the requirement for this pathway in older embryos and mature 
animals. In the present study, we used anti-CLEC2 antibodies that 
rapidly induce CLEC2 deficiency in vivo to determine the requisite 
sites of platelet-LEC interaction. Our studies revealed that plate-
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lets interact with lymphatic endothelium specifically at the TD-SV 
junction and that blood-filled lymphatics arise due to backfilling 
of the lymphatic vascular network from this site. Identical find-
ings were observed in fully mature animals after reconstitution 
with Clec2–/– hematopoietic cells, which indicates that this hemo-
static requirement exists throughout life, even in animals with 
entirely normal lymphatic development and function. Analysis 
of mice lacking LVVs or lymphatic valves revealed that valves and 
platelet-mediated lymphovenous (LV) hemostasis function togeth-
er to maintain blood-lymphatic separation. These results identify 
an unexpected role for platelets in mediating a specialized form 
of intervascular hemostasis that differs markedly from the better-
characterized role of platelets in high shear, arterial hemostasis, 
and thrombosis. Our findings raise important questions regarding 
the role of this LV hemostatic pathway in pathologic states and in 
patients treated with drugs that block platelet function.
Results
Anti-CLEC2 antibodies rapidly confer blood-filled lymphatics in the intes-
tine of postnatal animals. Loss of CLEC2 signaling in late-gestation 
embryos and in mature animals reconstituted with Clec2–/– hema-
topoietic cells resulted in blood-filled lymphatics throughout the 
intestine (Figure 1, A and B). Clec2–/– postnatal animals also exhib-
ited large pleural effusions that were associated with respiratory 
distress and death (Figure 1C). To define the sites of platelet-LEC 
interaction at which PDPN-CLEC2 signaling is required to pre-
vent this phenotype, we performed extensive histologic staining 
for platelets and LECs in the intestine of wild-type late-gestation 
embryos and neonates. In contrast to a similar histologic analysis 
that revealed platelet-LEC interactions in the cardinal vein of the 
E11.5 embryo (4), the present studies failed to reveal any sites at 
which platelets associated with LECs (N > 100 sections stained). 
These findings suggest either that histologic analysis is not sensi-
tive enough to identify important sites of platelet-LEC interaction 
within the intestine or that blood-lymphatic mixing in the intestine 
might arise due to loss of platelet-LEC interaction at a distant site.
To define where platelet-LEC interaction is necessary, we adopted 
an anatomic strategy in which we rapidly induced a CLEC2 defi-
ciency state in neonates and searched for the earliest sites of blood 
appearance in the lymphatics. CLEC2 deficiency was induced by 
injection of the rat anti-mouse CLEC2 antibody INU1 in wild-type 
neonates. INU1 injection in mature animals has previously been 
shown to result in a transient thrombocytopenia that is followed 
by an extended period of complete platelet CLEC2 deficiency (13). 
Consistent with these findings, injection of INU1 induced a rapid 
and virtually complete loss of platelet CLEC2 receptors in neonatal 
mice (Figure 1D). This was a CLEC2-specific effect, as the levels 
of the platelet receptor GP1b were unchanged (Figure 1D). INU1-
injected neonates developed blood-filled lymphatics in the intes-
tine and mesentery identical to those observed in Clec2–/– neonates 
as soon as 4 days after antibody administration (Figure 1E). These 
studies confirmed that CLEC2 signaling is required to prevent 
blood from entering the lymphatic network after birth and defined 
a means by which to trace the sites where platelet-LEC interaction is 
required to prevent this phenotype in postnatal animals.
Blood enters the intestine from mesenteric lymphatics in Clec2–/– ani-
mals. Lymphatic flow in the intestine begins with villous lacteals 
that connect to submucosal lymphatics and subsequently drain 
into mesenteric collecting lymphatics. Mesenteric collecting lym-
phatics drain through mesenteric LNs and merge at the cisterna 
chyli to form the TD. To determine the sites of origin of blood in 
the intestinal lymphatics of Clec2–/– mice, we examined animals 
between 4 and 6 days after INU1 injection, the period of time dur-
ing which the first blood-filled vessels were observed (Figure 1E). 
This spatiotemporal analysis revealed 3 distinct patterns of blood-
filled lymphatics in the abdomen of live animals. In the first, blood 
was only observed in mesenteric LNs, but not in lymphatic vessels 
of the mesentery or the intestine (Figure 2, A and B). In the sec-
ond, blood was observed in both mesenteric LNs and mesenteric 
lymphatics, but not in lymphatic vessels of the intestine (Figure 
2C). In the third, blood was observed at all 3 sites (Figure 2D). 
These patterns of blood-filled lymphatics were consistent with 
a previous study that described variable degrees of blood-filled 
lymphatics in the intestine and mesentery of mature mice recon-
stituted with SLP-76–deficient hematopoietic cells, with the mild-
est being the presence of blood-filled mesenteric LNs (14). These 
unexpected findings suggested that blood enters the lymphatics 
of the intestine from mesenteric lymphatics, rather than vice versa, 
in the absence of CLEC2 function. Thus, blood-filled lymphatics 
in the intestine of mice lacking PDPN-CLEC2 signaling are not 
the consequence of a primary vascular defect in the intestine itself, 
but instead arise secondarily as blood fills mesenteric lymphatics.
Blood-filled lymphatics arise in Clec2–/– animals lacking LNs. LNs 
develop in association with lymphatic vessels, contain closely 
apposed blood and lymphatic vascular networks, and are blood-
filled throughout the lifetime of mice lacking PDPN-CLEC2 sig-
naling (8, 14). We therefore hypothesized that the blood observed 
in mesenteric lymphatics shortly after loss of CLEC2 might origi-
nate in mesenteric LNs. To test this possibility, we examined Clec2 
deficiency in mice that lack the cytokine LTA or the transcription 
factor RORC (also known as RORgt). Lta–/– and Rorc–/– animals 
failed to form LNs and other secondary lymphoid organs, such 
as Peyer’s patches, due to an early defect in secondary lymphoid 
organ development (Figure 2E and refs. 15, 16). Lta–/–Clec2–/– and 
Rorc–/–Clec2–/– neonates exhibited blood-filled intestinal and mes-
enteric lymphatics like those observed in Clec2–/– neonates (Figure 
2F). INU1 injection of Lta–/– and Rorc–/– neonates resulted in blood-
filled intestinal and mesenteric lymphatics in a pattern similar to 
those observed in wild-type animals (Figure 2G). Finally, blood-
filled intestinal and mesenteric lymphatics were also observed 
in lethally irradiated Lta–/– and Rorc–/– adult animals that were 
reconstituted with Clec2–/– hematopoietic cells (Figure 2H). These 
pharmacologic and genetic studies demonstrated that LNs are not 
required for the development of blood-filled mesenteric lymphatic 
vessels in perinatal or mature Clec2–/– animals (Figure 2I).
The LV junction is the site of blood entry into the lymphatic network after 
loss of CLEC2. The finding that blood entered the intestine from 
mesenteric lymphatic vessels in a manner independent of mes-
enteric LNs after CLEC2 loss suggested that the critical site of 
platelet interaction must lie in the most terminal portion of the 
lymphatic network, most likely the TD (Figure 3A). To test this 
hypothesis, we examined the TD at early time points after INU1-
induced CLEC2 deficiency. The TD was readily visualized by the 
presence of chyle or by the presence of fluorescent dextran after 
injection into the footpad (Figure 3B), which indicates that for-
ward lymphatic flow is present in some animals that exhibit blood 
in the lymphatic network. Analysis of INU1-injected neonates at 
earlier time points revealed blood in the TD in the chest prior to 
detection of blood in mesenteric LNs or mesenteric-collecting 
lymphatics in the abdomen (Figure 3C). In addition, blood was 
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Figure 1
Loss of CLEC2 results in blood-filled lymphatics in the 
intestine of both perinatal and mature mice. (A) Genetic 
deletion of Clec2 resulted in blood-filled lymphatics in 
the skin at midgestation (top) and in the small intes-
tine at birth (bottom). (B and C) Mature wild-type mice 
reconstituted with Clec2–/– hematopoietic cells exhibited 
blood-filled intestinal lymphatics (B) and large, bloody 
pleural effusions (C). (B) Images of the intestine were 
obtained 5.5 weeks after transplantation of the indicated 
hematopoietic cells. Respiratory distress and death were 
observed in animals with Clec2–/–, but not Clec2+/+ or 
Clec2+/–, hematopoietic cells. (C) Pleural effusion fluid 
was obtained at the time of sacrifice. The survival curve 
of a transplantation cohort is also shown. A large pleural 
effusion was observed in all 6 Clec2–/– recipients. (D) i.p. 
injection of the anti-CLEC2 antibody INU1 at P1 resulted 
in a sustained CLEC2 deficiency state. Shown is flow 
cytometry of circulating platelets stained with anti-CLEC2 
or anti-GP1b antibodies. (E) INU1-mediated CLEC2 defi-
ciency conferred blood-filled intestinal lymphatics. Images 
of intestine at P5, after a single INU1 injection at P1 (left), 
or at P14, after injection at P1, P5, and P9 (middle and 
right). Arrows indicate lymphatic vessels. Boxed regions 
are shown at higher magnification (enlarged ×3). V, vein; 
A, artery, L, lymphatic.
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Figure 2
Blood enters lymphatic vessels of the intestine via backflow from mesenteric-collecting lymphatics in Clec2–/– animals. (A) Normal anatomy of 
the mesentery and intestine at P6. Lymphatic vessels of the intestine and mesentery are white due to the presence of chyle. Shown are a mes-
enteric LN and a schematic of the lymphatic network at this site. (B–D) 3 patterns of blood-filled lymphatics were observed between P5 and P7 
after anti-CLEC2 antibody injection at P1: (B) blood only in mesenteric LNs; (C) blood in mesenteric LNs and mesenteric lymphatic vessels, but 
not intestinal lymphatics; and (D) blood in mesenteric LNs, mesenteric lymphatics, and intestinal lymphatics. Dotted outline in B denotes LN; 
arrows in D indicate lymphatic vessels. (E) Lta–/– neonates lacked mesenteric LNs. Images were obtained at P1. (F) Clec2–/– animals developed 
blood-filled lymphatics in the intestine on Lta–/– and Rorc–/– backgrounds. Images were obtained at P1. (G) Lta–/– and Rorc–/– neonates developed 
blood-filled lymphatics after injection of anti-CLEC2 antibody. Antibody was injected at P1 and P5, and images were obtained at P9. (H) Lta–/– and 
Rorc–/– mature animals developed blood-filled lymphatics after reconstitution with Clec2–/– hematopoietic cells. Images were obtained 8 weeks 
after transplantation. (I) Lta or Rorc deficiency does not prevent blood from entering the intestines of Clec2–/– animals.
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observed in the most terminal portion of the TD — immediately 
preceding the TD-SV junction — when no blood was present in 
more proximal portions of the TD closer to the intestine (Figure 
3C). These findings suggest that blood enters the lymphatic sys-
tem at the LV junction, where the TD joins the SV, and that the 
intestine and other lymphatic vascular beds are filled secondarily 
by retrograde blood flow.
Aspects of lymphatic growth such as valve maturation are 
believed to take place and/or be reversible in the perinatal peri-
od (17). It is therefore possible that retrograde entry of blood 
into the terminal TD in Clec2–/– neonates could arise secondary 
to effects of blood-filled lymphatics on valve development and 
maturation, and not reflect a primary hemostatic requirement 
in the presence of normal LVVs and lymphatic valves. To distin-
guish between these possibilities, we performed similar-timed 
CLEC2 deficiency experiments in mature 12-week-old wild-type 
animals that were lethally irradiated and reconstituted with 
Clec2–/– hematopoietic cells. Analysis of these animals 3 weeks 
after reconstitution revealed the presence of blood in the TD 
prior to its detection in mesenteric LNs, mesenteric collecting 
lymphatics, or lymphatics in the intestine wall (Figure 3D). These 
findings demonstrated that CLEC2-mediated platelet activation 
is required in healthy animals to prevent retrograde filling of the 
lymphatic system with venous blood even after normal LVV and 
lymphatic valve development (Figure 3E).
SYK inhibition with fostamatinib disodium (R788) does not result in 
entry of blood into the lymphatic network. Genetic studies indicate that 
SYK is absolutely required for CLEC2 signaling in platelets (6), and 
Syk-deficient neonates and adult radiation chimeras exhibit lethal 
blood-lymphatic vascular mixing phenotypes identical to those 
of Clec2-deficient animals (9, 18, 19). It is therefore possible that 
novel SYK inhibitors developed to treat chronic inflammatory dis-
orders such as rheumatoid arthritis may confer blood-lymphatic 
phenotypes like those associated with lymphatic dysfunction and 
death in genetic models and anti-CLEC2 antibody treatment. To 
test the effect of such inhibitors, we treated wild-type neonates for 
8 days with the SYK antagonist fostamatinib disodium (R788) at 
doses higher than those shown to be effective in alleviating symp-
toms of experimental arthritis in a rat model (20). Fostamatinib 
is a prodrug that is rapidly converted to R406, with a plasma half-
life of less than 2 hours in mice (21). In contrast, R788 has a half-
life of approximately 15 hours in humans, where SYK inhibition 
is more sustained (22). Therefore, we administered fostamatinib 
every 6 hours to more accurately model human use. Unlike treat-
ment with the antibody INU1 (Figure 3C), fostamatinib treatment 
did not result in detectable entry of blood into the TD (n = 6; Fig-
ure 3F). As discussed further below, these findings suggest that 
very-high-level loss of SYK or CLEC2 function is required to confer 
blood-lymphatic mixing in healthy animals.
Platelet thrombi form at the LV junction in wild-type mice, but not Clec2–/– 
mice. Bicuspid valves at the LV junction are thought to prevent 
venous blood from entering the lymphatic vascular network (Fig-
ure 4A and ref. 2), but the studies described above suggested that 
platelet-LEC interaction and CLEC2-mediated platelet activation 
might also be required. To test for platelet-LEC interaction at this 
site, we examined the left LV junction, where the TD meets the 
SV. The TD-SV junction was identified in E17.5 embryos by its 
characteristic location below the clavicle and at the intersection 
of the internal jugular vein and SV, and by the presence of a bicus-
pid LVV. As recently described (23), immunostaining of the LVV 
revealed the presence of PROX1+ endothelial cell nuclei on both 
sides of the valve, but the LEC-specific surface proteins PDPN and 
LYVE1 were selectively expressed on the lymphatic side, not the 
venous side, of this unique valve (Figure 4B). Small platelet aggre-
gates were observed immediately at the LVV, and larger thrombi 
containing both platelets and erythrocytes were observed along 
the PROX1+LYVE1+ lymphatic endothelium within the neighbor-
ing TD, in a fraction of wild-type animals (n = 4 of 14; Figure 4C). 
In contrast, analysis of the TD-SV junction in Clec2–/– embryos 
revealed no platelet aggregates or thrombi, despite the presence of 
blood filling the TD (n = 0 of 4; Figure 4D). Notably, LVV structure 
and size in Clec2–/– embryos was indistinguishable from that of 
wild-type littermates (compare Figure 4, B and C). These observa-
tions indicate that platelet-LEC interactions and platelet thrombi 
form in a CLEC2-dependent manner in the region of the LV junc-
tion, despite the presence of the LVV.
LV hemostasis supports valve function to maintain blood-lymphatic sepa-
ration. The studies described above suggested that CLEC2-medi-
ated platelet activation may function together with the LVV to 
prevent blood from entering the TD, even in healthy animals with 
normal valve development and function. To better understand the 
interaction of these 2 protective mechanisms, we next examined 
the role of platelets in mice with normal PDPN-CLEC2 signaling, 
but impaired valve function. PROX1 was strongly expressed on 
both blood and lymphatic valve endothelium, and Prox1+/– mice 
lacked LVVs (Figure 5A and ref. 23). Integrin α9 is selectively 
expressed on venous and lymphatic valve endothelium, and Itga9–/– 
mice lack lymphatic valves (24, 25). We detected normal-appear-
ing LVVs in Itga9–/– mice (Figure 5A), but whether they function 
normally is not known. Histologic analysis of the TD in E17.5 
Prox1+/– and Itga9–/– animals revealed the presence of large plate-
let thrombi both at the LVV and throughout the TD (Figure 5, 
B–D). In contrast to those in wild-type animals, platelet thrombi 
in Prox1+/– and Itga9–/– animals were both more spatially extensive 
(i.e., located in more proximal regions of the TD, far from the 
LV junction; Figure 5D) and more prevalent (i.e., observed in all 
6 Itga9–/– animals and all 5 Prox1+/– animals examined). In con-
trast, only a subset of E15–E16 Prox1+/– animals exhibit blood-
filled lymphatic vessels in the skin (23), while no Itga9–/– animals 
exhibit this phenotype (24). Thus, LV hemostasis can compensate 
for loss of LVV and lymphatic valve function to maintain blood-
lymphatic separation in vivo.
LV hemostasis involves fibrin formation and platelet aggregation. 
Our findings revealed an unexpected role for platelet activation 
in blocking the retrograde entry and passage of venous blood 
into the lymphatic network. Most previously described plate-
let responses have been in the setting of arterial shear and vessel 
injury. In contrast, the terminal TD is predicted to be a site of low 
flow and low shear, raising the question of whether and to what 
extent platelet-mediated LV hemostasis uses the same mechanisms 
as more classic platelet responses. One such mechanism is platelet 
procoagulant activity that promotes thrombin and fibrin clot for-
mation. Platelet aggregates observed in wild-type animals stained 
strongly for fibrin (Figure 6A), which indicates that CLEC2-medi-
ated platelet aggregates at the LV junction drive the formation 
of fibrin-containing thrombi. A second canonical endpoint of 
platelet activation in the setting of vessel injury is the activation 
of integrin aIIbb3 receptors that mediate platelet cross-linking 
and shear-resistant aggregate formation. To test the role of this 
mechanism in LV hemostasis, we next analyzed the LV junction of 
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Figure 3
Blood is first observed in the TD after loss of Clec2 in both neonates and mature animals. (A) Terminal lymphatic network between the intestine 
and LV junction. Dotted lines denote level of the diaphragm. (B) The TD at P6 was detected adjacent to the vertebral column in the chest by the 
presence of FITC-dextran after injection into the hindlimb. Boxed regions are shown enlarged at right. (C) Blood was detected in the TD prior 
to the lymphatics of the mesentery and intestine after loss of CLEC2. Shown are TD (top left) and abdomen (top right) of a P6 wild-type animal 
injected with anti-CLEC2 antibodies on P1 after FITC-dextran injection. Arrows indicate blood in the TD. Note the absence of blood in lymphatics 
of the intestine (top) and its presence in the terminal region of the TD near the LV junction (bottom). (D) 12-week-old wild-type mice were lethally 
irradiated and reconstituted with Clec2–/– hematopoietic cells, and the TD was imaged 3 weeks later. Arrows indicate blood in the TD. Note the 
absence of blood in lymphatics of the intestine (top right). Blood was first observed in the terminal region of the TD near the LV junction after 
reconstitution (bottom). (E) Path of blood from the TD to the lymphatics of the mesentery and intestine after induced CLEC2 deficiency. (F) TD 
after 8 days of fostamatinib treatment of wild-type mice. Blood was not detected in the TD (n = 6).
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E17.5 Itgb3–/– embryos. LV thrombi were evident in all 4 Itgb3–/– ani-
mals examined (Figure 6B), which indicates that platelet aggrega-
tion is not absolutely required for thrombus formation. However, 
Itgb3–/– animals also exhibited a large amount of blood and throm-
bi in the TD that was not seen in control littermates (Figure 6C), 
which suggests that platelet aggregation may function to stabilize 
thrombi that form in the lymphatic vascular environment. These 
results identified platelet thrombus formation as the key endpoint 
of PDPN-CLEC2 signaling and provided further evidence for a 
hemostatic mechanism of blood-lymphatic separation.
Figure 4
Platelet thrombi are observed at the 
LV junction in wild-type mice, but not 
Clec2–/– mice. (A) LV junction in the 
coronal and sagittal planes, includ-
ing some anatomic variants like those 
described below. (B) LV junction of a 
wild-type E17.5 embryo in the sagit-
tal plane. PROX1 was detected in 
endothelial nuclei on both the venous 
(SV) and lymphatic (TD) sides of the 
LVV, whereas PDPN and LYVE1 were 
detected exclusively on the lymphatic 
side. (C) Platelet thrombi (arrows) were 
detected at the LVV and adjacent to 
lymphatic endothelium in the nearby 
TD in wild-type animals. (D) Blood filled 
the TD at the LV junction in Clec2–/– ani-
mals, but no thrombi were observed. 
Dotted outlines denote vessel walls. JV, 
jugular vein. Scale bars: 50 μm.
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Figure 5
Large platelet thrombi are observed 
throughout the TD of Prox1+/– and Itga9–/– 
animals. (A) Representative LVVs and lym-
phatic valves in Prox1+/– and Itga9–/– mice, 
which had impaired valve development. 
Valve rudiments are labeled and/or denot-
ed by arrows. (B) Platelet-containing throm-
bi were observed in the TD adjacent to the 
SV in E17.5 Prox1+/– embryos. (C) Platelet-
containing thrombi were observed next to 
the LVV and in the TD adjacent to the SV 
in E17.5 Itga9–/– embryos. (D) Platelet-con-
taining thrombi extended to the proximal TD 
in the chest of E17.5 Prox1+/– and Itga9–/– 
embryos. Dotted outlines denote vessel 
walls. Scale bars: 50 μm.
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changes in pressure generated by the heart. In contrast, lymph is 
acquired from the tissues through an open, permeable vascular 
network in which flow is maintained by the contraction of col-
lecting vessel walls, external compression, and valves. Lymph must 
Discussion
Blood and lymphatic vessels play essential, complementary roles 
in vivo that require very different structures and function. Blood 
circulates in a closed vascular network in which flow is driven by 
Figure 6
LV hemostasis involves fibrin gen-
eration and platelet aggregation. 
(A) Platelet thrombi in the terminal 
TD of wild-type animals contained 
abundant fibrin. (B) The LV junction 
and terminal TD of E17.5 Itgb3–/– 
embryos contained numerous 
fibrin+ platelet thrombi. (C) Blood 
was present in the proximal TD in 
the chest of E17.5 Itgb3–/– embryos 
despite thrombus formation. Scale 
bars: 50 μm.
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reveal an essential mechanism of platelet-mediated hemostasis 
that operates completely within an uninjured intravascular envi-
ronment, and under low-flow, low-shear conditions. Our prelimi-
nary characterization of this hemostatic pathway revealed that it 
uses platelet activation to drive procoagulant activity and forma-
tion of fibrin-containing thrombi. Consistent with the observa-
tion that mice lacking the platelet aIIbb3 integrins do not exhibit 
blood-filled lymphatics like those lacking CLEC2 signaling (30), 
thrombus formation in LV hemostasis did not require integrin 
aIIbb3–mediated platelet aggregation (Figure 6B). However, we did 
observe impaired LV hemostasis in Itgb3–/– animals (Figure 6C). 
These findings suggest that multiple known endpoints of platelet 
activation are likely to participate in LV hemostasis and provide 
important additional evidence for a hemostatic mechanism of 
blood-lymphatic separation.
An important paradox raised by our findings is how thrombi 
formed as a consequence of platelet-LEC interaction can sustain 
forward lymphatic flow while preventing backward blood flow. 
While the answer to this question is not yet clear, several possi-
bilities merit discussion. First, while blood circulates at a rate of 
5–6 l/min in the average human, lymph flow is only 3–5 l/d. Thus, 
thrombi that temporarily occlude the TD and are sufficient to 
prevent transient backflow of blood into the lymphatic network 
are not likely to have an immediate effect on lymphatic function. 
Second, since we observed robust fibrin formation, it is likely that 
LV thrombi are subject to lysis by fibrinolytic enzymes. Whether 
rapid clot lysis is more likely to take place in the lymphatic vascu-
lar environment (e.g., due to higher fibrinolytic activity in lymph 
versus plasma, as has been reported previously; refs. 31, 32) is an 
interesting possibility that remains to be tested.
The discovery of a specialized platelet hemostatic mechanism 
to prevent blood from entering the lymphatic system is surpris-
ing, given the existence of valves that protect both the LV junction 
and the TD from backward flow. Why are 2 mechanisms required? 
Recent genetic studies of vascular development and older physi-
ologic studies of lymphatic function identify several potential rea-
sons for the existence of a second, hemostatic mechanism. Genetic 
studies in mice revealed that both blood and lymphatic valves 
mature in late gestation and after birth, time points after forma-
tion of the LV junction and the onset of lymphatic function in the 
ultimately drain into the blood at the LV junction, but the open, 
low-pressure lymphatic system cannot function properly if it is 
exposed to blood vascular hemodynamic forces. In the present 
study, we demonstrated that platelet CLEC2 receptor signaling 
mediated an intervascular hemostasis that is required to safeguard 
the lymphatic system from these forces and maintain normal lym-
phatic function throughout life. We found that this LV hemostatic 
mechanism operates alongside, but is not redundant with, LVVs 
and lymphatic valves (Figure 7). Our present results define a novel 
type of platelet-mediated hemostasis and explain the complex vas-
cular phenotypes of mice lacking the PDPN–CLEC2–SYK–SLP-76– 
PLCg2 platelet activation pathway.
Analysis of Syk-deficient mice almost 20 years ago revealed an 
unexpected phenotype characterized by a “hemorrhagic” appear-
ance in midgestation embryos and fatal chylous ascites in neo-
nates (18, 19). Studies in the past decade have established that this 
phenotype is due to blood-filled lymphatics that arise as a result 
of loss of platelet activation by the CLEC2 receptor in response to 
the PDPN ligand expressed on LECs, but not on blood endothelial 
cells (4–6, 8, 26). However, precisely when and where platelets inter-
act with lymphatic endothelial PDPN, and how platelet activation 
prevents blood-lymphatic mixing, has remained mysterious. Our 
studies demonstrate that the blood-lymphatic mixing phenotypes 
in postnatal mice lacking this pathway reflect a requirement for 
platelet interaction with LECs at the LV connection where the 
TD connects to the SV. Since a primitive LV junction is present 
by E11.5 (23), it is possible that blood-filled lymphatics in prena-
tal mice lacking this pathway arise due to the same mechanism. 
Although it has been suggested that blood-filled lymphatics may 
arise due to loss of platelet granule contents that regulate lym-
phangiogenesis (5, 6), our findings support a unique intervascular 
hemostatic mechanism in which CLEC2-activated platelets gener-
ate thrombi that prevent blood from entering the lymphatic vas-
cular network at LV junction.
Our findings identify a novel mechanism of platelet-mediated 
hemostasis that is required for normal lymphatic function and 
survival. The present paradigm is one that defines the role of plate-
lets primarily by their formation of arterial, shear-resistant aggre-
gates in response to vessel injury and exposure of procoagulant 
molecules such as tissue factor (27–29). In contrast, our studies 
Figure 7
Maintenance of blood-lymphatic separation by LVV function and LV hemostasis. Examination of wild-type and mutant animals revealed the roles 
of the LVV and CLEC2-mediated LV hemostasis. Left: In healthy wild-type animals, LV hemostasis appears to function intermittently to block 
the retrograde movement of blood that enters the TD, despite normal LVV function. Middle: Impaired valve function, due either to abnormal LVV 
formation in Prox1+/– animals or to abnormal lymphatic valve formation in Itga9–/– animals, results in more extensive LV hemostasis that prevents 
backfilling of the lymphatic network with blood. Right: Loss of platelet CLEC2 function results in backfilling of the lymphatic network with blood 
despite normal LVV function, while loss of platelet aggregation results in a blood-filled TD despite the formation of platelet thrombi.
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LV hemostatic pathway in both health and disease is essential for 
understanding its potential clinical importance.
Methods
Mouse lines. Clec2–/– (4), Prox1+/– (39, 40), and Itga9–/– (41) animals have 
been described previously. Lta–/–, Rorc–/–, and Itgb3–/– mice were obtained 
from the Jackson Laboratory. Phenotypic analysis was conducted on 
Clec2–/–, Clec2–/–Lta–/–, Clec2–/–Rorc–/–, Prox1+/–, Itga9–/–, and Itgb3–/– animals 
with littermate controls.
Fetal liver transplantation. Fetal livers were isolated from E14.5–E17.5 
embryos, passed through a 70-μm cell strainer with DMEM, and injected 
i.v. into 6- to 8-week-old irradiated recipients (Cesium-137, 11 Gy, Gamma-
cell 40 Exactor; MDS Nordion). Drinking water contained trimethoprim/
sulfamethoxazole antibiotics for 4 weeks after transplantation.
INU1-mediated CLEC2 deficiency. Monoclonal rat anti-mouse CLEC2 anti-
body (clone INU1, IgG1) in PBS was injected i.p. at a dose of 8 μg/g body 
weight as described previously (13).
Fostamatinib administration to mice. An aqueous suspension of fostama-
tinib disodium (R788) at 4.0 mg/ml was fed orally to neonatal mice every 
6 hours at 40 mg/kg body weight beginning at P1 for 8 days.
Flow cytometry. Whole blood collected into heparinized PBS was 
immuno stained with antibodies to CLEC2 (clone INU1) and GP1bα (clone 
Xia.G5). Cells were incubated with antibody for 45 minutes, fixed with 5% 
formalin for 5 minutes, and stained as usual.
Fluorescent lymph contrast. FITC-dextran (MW 40,000; Sigma-Aldrich) in 
PBS was injected into the hindlimbs at 10 mg/ml, and lymphatic vessels 
were imaged 2 hours later.
Histologic analysis. Paraffin-embedded tissue sections were immuno-
stained or H&E stained. Immunofluorescence was performed with 
polyclonal anti-mouse antibodies for platelets (Inter-Cell Technologies 
Inc.), fibrin(ogen) (Santa Cruz Biotechnology), PDPN (R&D), PROX1 
(Abcam), and LYVE-1 (R&D). Histologic images were acquired with a 
Nikon Eclipse 80i microscope using a ×20/0.50 or ×40/0.75 numeric apera-
ture (NA) dry objective.
Statistics. Kaplan-Meier survival curves were compared using both the log-
rank (Mantel-Cox) test and the Gehan-Breslow-Wilcoxon test on Prism 5.0 
(GraphPad Software). A P value less than 0.05 was considered significant.
Study approval. Animal protocols were approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee.
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developing animal (17, 23, 25). Thus, it is likely that this hemo-
static mechanism is initially required to safeguard the lymphatic 
system during the process of valve development and maturation. 
This possibility is supported by the observation that Itga9–/– neo-
nates die shortly after birth due to a complete absence of lymphat-
ic valves, but do not exhibit blood-filled lymphatics. However, our 
finding that blood rapidly entered the TD of adult animals with 
normal valves after reconstitution with Clec2–/– hematopoietic cells 
(Figure 3G) revealed that LV hemostasis was required even after 
valve development was complete. This ongoing requirement most 
likely reflects important differences in fluid dynamics between 
the venous and lymphatic systems that would drive blood into the 
lymphatic system. Central venous pressure is 5–10 mm Hg under 
resting conditions (33), but is highly dynamic and changes during 
respiration, with changes in body position and fluid status, and in 
disease states such as congestive heart failure (CHF). In contrast, 
lymphatic pressures are typically low, at 1–2 mmHg (34), and ele-
vation of TD pressure beyond 6 mm Hg virtually halts lymphatic 
flow (35). Thus, even small amounts of intermittent backflow of 
blood might raise lymphatic pressures and obstruct lymphatic 
flow. Analogous to the role of hemostasis in maintaining blood 
vessel integrity, LV hemostasis is probably not a primary means of 
separating the blood and lymphatic vasculatures in mature ani-
mals, but instead most likely functions as a safety mechanism by 
which to protect lymphatic function.
The discovery of a platelet-mediated hemostatic mechanism 
required to safeguard the lymphatic system has important clini-
cal implications. A recent ultrasound study of the LV junction 
in live human patients revealed that elevated central venous 
pressures due to chronic CHF can be associated with LVV insuf-
ficiency, reflux of blood into the TD, and dilatation of the TD 
(36). These findings are consistent with our findings that mice 
with deficient valve function exhibited extensive TD thrombus 
formation (Figure 5) and suggest that the role of platelet-medi-
ated LV hemostasis in safeguarding the lymphatic system might 
be augmented in patients with CHF. Such patients are frequently 
treated with antiplatelet drugs to reduce the risk of myocardial 
infarction and stroke; whether such therapies also compromise 
lymphatic function and exacerbate respiratory symptoms associ-
ated with pulmonary edema is not yet known. A second clinical 
issue raised by our studies concerns the safety and long-term lym-
phatic vascular effects of SYK antagonists that have been devel-
oped to treat chronic inflammatory disorders such as rheumatoid 
arthritis (37, 38). Genetic studies in mice clearly demonstrate that 
complete loss of SYK function confers blood-lymphatic mixing 
in both developing and mature animals as a result of its effects 
on platelet CLEC2 signaling (9, 19). In contrast, we found that 
pharmacologic loss of SYK function conferred by fostamatinib 
treatment in mice was not sufficient to confer blood-lymphatic 
mixing at doses capable of treating a rodent model of arthritis 
(Figure 3F). These results are encouraging for anti-SYK agents, 
but whether patients who are also taking more effective anti-
SYK agents or other antiplatelet drugs and/or have chronically 
elevated venous pressure (e.g., in association with CHF) will be 
similarly protected is not yet clear. Understanding the role of this 
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